Search
Returning search results with filters:
Remove filter for
Issue: COVID
Remove filter for
Last updated: 2023
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 1 of 1 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17